MARCH 31, 2018
Jupiter, FL: Cytonics Corporation, a biotechnology company focused on the development of biologic therapies for musculoskeletal diseases, today announced that the World Intellectual Property Organization issued patent WO 2013/126587 Al covering both a biological preparation of concentrated Alpha-2-Macroglobulin (A2M) and a recombinant variant of the naturally occurring A2M molecule. Cytonics’ APIC-PRP system concentrates and purifies A2M from patients’ blood, producing a therapeutic composition that is injected into damaged joints. This proprietary technology is being developed to treat cartilage degeneration in diseases such as osteoarthritis.

Alpha-2-Macroglobulin (A2M) is an abundant, endogenous blood protein that inhibits all classes of serine proteases and metalloproteases, thereby decreasing protein degradation involved in osteoarthritis and attenuating joint pain. Cytonics’ recombinant Alpha-2-Macroglobulin variant,
Cyt-108, is a synthesized protein that contains a series of mutations within the bait region of the protein structure. The mutated bait region was designed to increase the potency of the A2M molecule, allowing small doses to have large therapeutic effects.

Our recombinant A2M drug development program is cutting edge. The mere fact that we were able to purify such a large protein from mammalian cells is a scientific feat. We have shown that the purified Cyt-108 is enzymatically active in vitro. We are extremely confident that Cyt-108 will demonstrate efficacy in clinical trials because we have already experienced clinical success in treating osteoarthritis with our autologous A2M therapy (APIC-PRP).

Joey Bose
President of Cytonics

About Cytonics:

Cytonics, founded in 2006, is a private research and development company focusing on molecular diagnostic and therapeutic products for chronic musculoskeletal diseases. The company developed the FACT diagnostic test which helps identify the source of back and joint pain and assists physicians in determining the most appropriate treatment. Cleared in January of 2014, Cytonics developed the Autologous Platelet-Integrated Concentrate (APIC) System as a platelet rich-plasma (PRP) device. In addition, the company also developed autologous cell-free A2M
concentrate and other forms of A2M therapeutics, including optimized recombinant forms. The company is currently pursuing pre-clinical studies for their lead recombinant A2M candidate, Cyt-108.

658 W. Indiantown Rd. Suite 214
Jupiter, FL 33458
561-406-2864
Cytonics.com